Condition: Non-Arteritic Anterior Ischemic Optic Neuropathy · Sponsor: Dompé Farmaceutici S.p.A
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).
This description comes directly from the study's public registry record.
Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI) · +39 02 583 831
Always discuss trial participation with your own doctor first.
| Neuro Eye Orbit Institute | Los Angeles, California, United States | Recruiting |
| David Geffen School of Medicine at UCLA - Ophthalmology | Los Angeles, California, United States | Not Yet Recruiting |
| California Orbital Consultants | Newport Beach, California, United States | Not Yet Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Bascom Palmer Eye Institute, University of Miami School of Medicine | Miami, Florida, United States | Not Yet Recruiting |
| Sarasota Retina Institute - Research | Sarasota, Florida, United States | Not Yet Recruiting |
| Northwestern University - Ophthalmology | Chicago, Illinois, United States | Not Yet Recruiting |
| University of Illinois at Chicago Eye and Ear Infirmary - Ophthalmology | Chicago, Illinois, United States | Not Yet Recruiting |
| Univ. Of Kentucky Clinic Dept of Ophthalmology & Vision Science | Lexington, Kentucky, United States | Not Yet Recruiting |
| The Johns Hopkins Hospital (JHH) | Baltimore, Maryland, United States | Not Yet Recruiting |
| Tufts Medical Center - Neurology | Boston, Massachusetts, United States | Not Yet Recruiting |
| University of Michigan Health - Kellogg Eye Center | Ann Arbor, Michigan, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07453888